Clinical Focus

  • Infectious Disease

Academic Appointments

Professional Education

  • Fellowship: Stanford University Infectious Disease Fellowships (2019) CA
  • Board Certification: American Board of Internal Medicine, Infectious Disease (2018)
  • Fellowship: Stanford University Infectious Disease Fellowships (2018) CA
  • Residency: California Pacific Medical Center Internal Medicine Residency (2016) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2015)
  • Medical Education: New York Medical College Registrar (2012) NY

Contact

  • Clinical (Primary)  Infectious Disease Clinic 450 Broadway St Pavilion A, Ground Floor Redwood City, CA 94063 (650) 736-0175 (fax)

Additional Clinical Info

All Publications

  • No differences in outcomes with stopping or continuing antibiotic suppression in periprosthetic joint infections. Journal of bone and joint infection Furukawa, D., Dunning, M., Shen, S., Chang, A., Aronson, J., Amanatullah, D. F., Suh, G. A., Kappagoda, S. 2024; 9 (3): 143-148

    Abstract

    The data on long-term antibiotic use following debridement, antibiotics, and implant retention (DAIR) for treatment of periprosthetic joint infections are limited. In this single-center retrospective study, we show that patients with eventual cessation of antibiotic suppression after DAIR had similar outcomes to those who remained on chronic antibiotic suppression.

    View details for DOI 10.5194/jbji-9-143-2024

    View details for PubMedID 38899055

    View details for PubMedCentralID PMC11184613

  • The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies. Viruses Liu, D., Van Belleghem, J. D., de Vries, C. R., Burgener, E., Chen, Q., Manasherob, R., Aronson, J. R., Amanatullah, D. F., Tamma, P. D., Suh, G. A. 2021; 13 (7)

    Abstract

    Increasing rates of infection by antibiotic resistant bacteria have led to a resurgence of interest in bacteriophage (phage) therapy. Several phage therapy studies in animals and humans have been completed over the last two decades. We conducted a systematic review of safety and toxicity data associated with phage therapy in both animals and humans reported in English language publications from 2008-2021. Overall, 69 publications met our eligibility criteria including 20 animal studies, 35 clinical case reports or case series, and 14 clinical trials. After summarizing safety and toxicity data from these publications, we discuss potential approaches to optimize safety and toxicity monitoring with the therapeutic use of phage moving forward. In our systematic review of the literature, we found some adverse events associated with phage therapy, but serious events were extremely rare. Comprehensive and standardized reporting of potential toxicities associated with phage therapy has generally been lacking in the published literature. Structured safety and tolerability endpoints are necessary when phages are administered as anti-infective therapeutics.

    View details for DOI 10.3390/v13071268

    View details for PubMedID 34209836

  • Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Aronson, J. R., Rezvani, A. R., Subramanian, A. n. 2019

    View details for DOI 10.1093/cid/ciz592

    View details for PubMedID 31297538